凝血因子XI与死亡率的非线性关联
Katsiaryna Prystupa1, Martin Heni2, Sebastian Hörber3
1Institute for Clinical Diabetology, German Diabetes Center (DDZ), Leibniz Center for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany; German Center for Diabetes Research (DZD), Partner Düsseldorf, Neuherberg, Germany.
Med (New York, N.Y.)
|December 27, 2025
概括
凝血因子XI (FXI) 活性显示了U形链接到冠状动脉疾病 (CAD) 患者的死亡率. 较高的FXI活动增加了CAD中的死亡风险,与非CAD个体不同.
科学领域:
- 心血管医学 心血管医学
- 血液静止研究 血液静止研究
- 临床试验 临床试验
背景情况:
- 凝血因子XI (FXI) 在血栓形成和心肌功能中起作用.
- 了解FXI对死亡率的影响对于治疗冠状动脉疾病至关重要.
研究的目的:
- 调查凝血因子XI (FXI) 活动与死亡风险之间的关联.
- 探索CAD和NT-proBNP水平如何改变这种关系.
主要方法:
- 分析了3,170名接受冠状动脉动图的参与者,其中67%被诊断为CAD.
- 平均随访时间为14.5年,使用Cox模型评估死亡风险.
- 探索FXI活动,NT-proBNP和CAD状态之间的相互作用.
主要成果:
- 观察到FXI活动和死亡率之间的U形关联 (p=0.027),FXI活动的最低风险为115.6%.
- 这种U形模式在没有CAD的患者中持续存在.
- 在CAD患者中,更高的FXI活性与增加的死亡率呈现线性相关性 (p-相互作用<0.0001),因NT-proBNP水平显著改变.
结论:
- FXI活动在血液静止中起着双重作用,对药物开发有影响.
- 针对FXI的治疗策略可能需要基于心血管疾病的个性化.
- 未来的FXI抑制剂研究必须考虑像CAD和NT-proBNP这样的调节因子,以优化疗法.
相关概念视频
Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Coagulation
1.2K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.2K
Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K


